Bicara Therapeutics BCAX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Bicara Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's cash ratio?
- Bicara Therapeutics (BCAX) reported cash ratio of 8.2× in Q1 2026.
- How has Bicara Therapeutics's cash ratio changed year-over-year?
- Bicara Therapeutics's cash ratio decreased by 66.0% year-over-year, from 24.2× to 8.2×.
- What is the long-term trend for Bicara Therapeutics's cash ratio?
- Over 2 years (2023 to 2025), Bicara Therapeutics's cash ratio has grown at a -53.2% compound annual growth rate (CAGR), from 15.3× to 3.3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.